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Background/Aims: In Asia, the incidence of non-Hodgkin lymphoma (NHL) has 
increased in recent decades. Waldeyer’s ring (WR) is the most common site of 
NHL involving the head and neck. In this study, the pathological distribution of 
WR-NHL and its clinical features were analyzed retrospectively.
Methods: From January 2000 through December 2010, we analyzed the medical 
records of 328 patients from nine Korean institutions who were diagnosed with 
WR-NHL.
Results: The study group comprised 197 male and 131 female patients with a 
median age of 58 years (range, 14 to 89). The rate of localized disease (stage I/II) 
was 64.9%, and that of low-risk disease (low/low-intermediate, as defined by the 
International Prognostic Index) was 76.8%. Diffuse large B-cell lymphoma (DL-
BCL; 240 patients, 73.2%) was the most common pathologic subtype, followed by 
peripheral T-cell lymphoma (14 patients, 4.3%) and nasal NK/T-cell lymphoma (14 
patients, 4.3%). WR-NHL occurred most frequently in the tonsils (199 patients, 
60.6%). Extranodal involvement was greater with the T-cell subtype (20 patients, 
42.5%) compared with the B-cell subtype (69 patients, 24.5%). Multivariate anal-
yses showed that age ≥ 62 years, T-cell subtype, and failure to achieve complete 
remission were significant risk factors for overall survival.
Conclusions: DLBCL was found to have a higher incidence in Korea than those 
incidences reported by other WR-NHL studies. T-cell lymphoma occurred more 
frequently than did follicular lymphoma. T-cell subtype, age ≥ 62 years, and com-
plete remission failure after first-line treatment were significant poor prognostic 
factors for overall survival according to the multivariate analysis.
Keywords: Head and neck; Non-Hodgkin lymphoma; Diffuse large B-cell lym-
phoma; T-cell lymphoma 
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INTRODUCTION
The prevalence of non-Hodgkin lymphoma (NHL) has 
increased in the last decade [1]. Immune-suppression, 
genetics, and exposure to chemical agents have con-
tributed to the increasing incidence of NHL [2-4]. NHL 
is not limited to lymph node progression; in contrast 
to Hodgkin lymphoma, it may arise from or involve 
extranodal organs in approximately one-third of cas-
es. Waldeyer’s ring (WR) is the most popular site of 
involvement among NHLs presenting in the head and 
neck. WR originates from lymphoid tissues surround-
ing the digestive and respiratory systems, including 
those around the Eustachian tube, upper palatine ton-
sils, nasopharynx, oropharynx, salivary glands, and 
sublingual sites. In Asia, NHL involving WR (WR-NHL) 
has increased recently [5-10].
The increased understanding of the pathology and 
physiology of lymphoma has led to changes in its clas-
sif ication. The World Health Organization (WHO) 
classification of lymphomas was revised in 2001 and 
again in 2008 [11,12]. However, recent studies of lym-
phomas involving WR were performed in few lympho-
ma subtypes and under limited circumstances. There-
fore, those studies were limited in their ability to 
determine the overall characteristics of WR-NHL. In 
this study, the clinical characteristics and pathological 
distribution of WR-NHL in Korea were analyzed ret-
rospectively according to the 2001 and 2008 WHO 
lymphoma classifications.
METHODS
From January 2000 through December 2010, 328 Ko-
rean patients pathologically confirmed as WR-NHL 
from nine independent institutions were reviewed 
retrospectively. Pathologic diagnosis was determined 
according to the 2001 and 2008 WHO classifications 
of lymphomas [11,12]. Patients were classified by the 
Ann Arbor staging system according to the results of 
computed tomography (CT) scans, positron emission 
tomography (PET)-CT, bone marrow biopsy, and ce-
rebrospinal f luid analysis if necessary. Clinical and 
laboratory parameters including age, sex, Eastern Co-
operative Oncology Group (ECOG) performance sta-
tus, and biochemical laboratory results were evaluated. 
The disease stage and extranodal involvement were 
also investigated. 
Patients with localized disease were classified into 
five groups according to their treatment: 1) supportive 
care; 2) chemotherapy alone; 3) chemotherapy plus ra-
diotherapy; 4) radiotherapy alone; and 5) surgical re-
section. The surgical resection group included pa-
tients who underwent chemotherapy or radiotherapy 
after surgery. We evaluated the treatment results and 
survival of each group using serial CT scans.
Progression-free survival (PFS), disease-free survival 
(DFS), and overall survival (OS) were analyzed using 
the Kaplan-Meier and the Cox proportional regression 
methods. PFS was calculated as the period from the 
first day of treatment to the date of disease progression 
or death from any cause. DFS was calculated as the pe-
riod from the date of complete remission (CR) to that 
of relapse or death while in CR. OS was calculated as 
the period from the first day of treatment to the date 
of death from any cause. The results were expressed as 
means with 95% confidence intervals (CIs) where ap-
propriate, and p < 0.05 was considered indicative of 
statistical significance. Statistical analysis was per-
formed using the PASW version 18.0 (SPSS Inc., Chica-
go, IL, USA). 
RESULTS
Patients
The median patient age was 58 years (range, 14 to 89). 
The male:female ratio of the 328 patients was 1.5:1. 
More than half of the patients (64.9%) presented with 
localized disease (Ann Arbor stage I or II). In particu-
lar, the majority of B-cell lineage NHL cases presented 
as localized disease (71.1%). T-cell lineage NHL cases 
more frequently showed disseminated disease (57%) 
compared with other NHLs. Most patients were in 
the low/low-intermediate risk group (252/328 patients, 
76.8%) according to the International Prognostic In-
dex (IPI) and had good performance status (ECOG 0; 
311/328 patients, 94.8%). Serum lactate dehydrogenase 
(LDH) levels were primarily in the normal range 
(280/328 patients, 85.4%). B symptoms (> 10% weight 
loss in 3 months, night sweats, and fever) were seen in 
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14% of the patients (Table 1). 
Pathologic distribution
The tonsils (60.6%) were the most common site of in-
volvement in WR-NHL, followed by the nasopharynx 
(6.4%), oropharynx (5.4%), sublingual site (4.8%), and 
salivary glands (1.8%). Of the cases with tonsillar in-
volvement, 15% (30 cases) also had involvement of the 
nasopharynx or oropharynx (Table 2).
B-cell lineage NHL (281 patients, 85.6%), compared 
with T-cell lineage NHL, was predominant among 
WR-NHL cases. Diffuse large B-cell lymphoma (DLB-
CL; 241/281 patients, 85.8%) was the most commonly 
observed subtype of B-cell lineage lymphoma. Periph-
eral T-cell lymphoma (14 patients, 4.3%), and NK/T-cell 
lymphoma (14 patients, 4.3%) were the most common 
subtypes of T-cell lineage WR-NHL. Other subtypes 
included extranodal marginal zone B-cell lymphoma 
(11 patients, 3.4%), mantle cell lymphoma (nine pa-
tients, 2.7%), and follicular lymphoma (four patients, 
1.2%). Other subtypes of NHL, excluding DLBCL, 
showed low prevalence (< 5%). 
Extranodal NHL
Extranodal NHL was observed in 89 patients (27.1%). 
Bone marrow was the most common site of involve-
ment (n = 30), followed by the gastrointestinal tract (n 
= 24); lung, pleura, and mediastinum (n = 16); bone (n 
= 10); and liver (n = 6). A small number of cases also 
involved the kidneys, ovaries, testis, cerebrospinal 
f luid, skin, nasal cavity, brain parenchyma, eyelid, 
conjunctiva, trachea, glottis or the thyroid gland. A 
total of 48 patients (14.6%) had one extranodal site of 
involvement, while 41 patients (12.5%) had more than 
one (Tables 3 and 4). Of the 281 patients with B-cell 
lineage lymphoma, extranodal involvement was ob-
served in 69 patients (24.5%). Of the 47 patients with 
T-cell lineage lymphoma, extranodal involvement was 
observed in 20 patients (42.5%); furthermore, a higher 
incidence was found in patients with nasopharyngeal 
involvement. In patients with DLBCL, the most com-
mon site of involvement was the gastrointestinal tract. 
Of the nine patients with mantle cell lymphoma, six 
had involvement of the bone marrow. 
Treatment outcomes and survival analyses
Patients with WR-NHL showed distinct differences 
in OS according to stage or IPI (Fig. 1). There were 227 
patients in the chemotherapy alone group (69.2%), 63 
patients in the chemotherapy plus radiotherapy group 
(19.2%), 16 patients in the radiotherapy alone group 
(4.9%), 17 patients in the surgical resection group 
(5.2%), and five patients in the supportive care group 
(1.5%). Most of the patients in the surgical resection 
group had DLBCL, and all received tonsillectomy. Of 
the surgical resection group, nine patients received 
chemotherapy, two received radiation therapy, and five 
Table 1. Baseline characteristics of Waldeyer’s ring 
non-Hodgkin lymphoma patients 
Characteristic No. (%)
Total                 328
Age, median (range), yr      58 (14–89)
Sex 
Male 197 (60.1)
Female  131 (39.9)
PS (ECOG)
≤ 1  311 (94.8)
> 1 17 (5.2)
IPA
Low/low-intermediate 252 (76.8)
High-intermediate/high   71 (21.6)
Unknown   5 (1.6)
Serum LDH level
Normal 280 (85.4)
Elevated  41 (12.5)
Unknown   7 (2.1) 
Ann Arbor stage
I/II  213 (64.9)
III/ IV 112 (34.1)
Unknown   3 (1.0)
B symptoms
Absent 279 (85.1)
Present  46 (14.0)
Unknown   3 (0.9)
Bone marrow involvement
Absent 298 (90.9)
Present 30 (9.1)
PS, performance status; ECOG, Eastern Cooperative Oncology 
Group performance status; IPI, International Prognostic 
Index; LDH, lactate dehydrogenase.
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received combined chemoradiotherapy after tonsillec-
tomy. One patient did not receive any additional treat-
ment after tonsillectomy (Table 5).
The median follow-up duration was 24.2 months 
(range, 0.2 to 106.1 months). The surgical resection 
group tended to have marginally better DFS compared 
with the chemotherapy alone group (2-year DFS rate, 
100% vs. 84.6% ± 4.8%; p = 0.097) or chemotherapy plus 
radiotherapy group (2-year DFS rate, 100% vs. 92.1% ± 
3.8%; p = 0.088). The surgical resection group also 
showed improved OS compared with the chemothera-
py alone group (2-year OS rate, 100% vs. 83.1% ± 4.2%; p 
= 0.036) or the chemotherapy plus radiotherapy group 
(2-year OS rate, 100% vs. 82.9% ± 5.0%; p = 0.025) (Fig. 2). 
Prognostic factors
In this study, patients aged ≥ 62 years were found to 
Table 2. Pathologic distribution of Waldeyer’s ring non-Hodgkin lymphoma cases 
Lymphoma subtype No. (%) Tonsil Nasopharynx Oropharynx
Base of 
tongue
Salivary 
gland
Oral 
cavity
Unknown
Diffuse large B-cell 
lymphoma
241 (73.5) 152 11 12 13 3 2 48
Mantle cell lymphoma   9 (2.7) 6 0 0 0 1 0 2
Follicular lymphoma   4 (1.2) 3 1 0 0 0 0 0
Small lymphocytic 
lymphoma
   3 (0.9) 1 1 0 0 0 0 1
Burkitt lymphoma   5 (1.5) 4 0 1 0 0 0 0
Extranodal marginal zone 
lymphoma of MALT
 11 (3.4) 4 2 1 1 0 0 3
T-cell-rich B-cell 
lymphoma
   3 (0.9) 0 0 0 0 1 0 2
Lymphoblastic 
lymphoma
   2 (0.6) 2 0 0 0 0 0 0
Nodal marginal zone 
lymphoma
  6 (1.8) 6 0 0 0 0 0 0
Peripheral T-cell 
lymphoma
14 (4.3) 6 4 1 1 1 0 1
Nasal NK/T-cell 
lymphoma
14 (4.3) 7 0 2 1 0 0 4
Angioimmunoblastic 
T-cell lymphoma
  9 (2.7) 5 1 0 0 0 0 3
Anaplastic large T-cell 
lymphoma
   3 (0.9) 2 0 0 0 0 0 1
Other T-cell lymphomas   5 (1.5) 1 1 1 0 0 1 1
Total 328 199 21 18 16 6 3 65
MALT, mucosa-associated lymphoid tissue.
Table 3. Extranodal site distribution of Waldeyer’s ring 
non-Hodgkin lymphoma (n = 328)
Variable No. (%)
No. of involved extranodal sites
0 239 (72.9)
1  48 (14.6)
≥ 2  41 (12.5)
Involved extranodal sites  
Bone marrow 30 (9.1)
Gastrointestinal tract 
(stomach/ileum/colon/rectum)
24 (7.3)
Lung/pleura/pericaridium 16 (4.8)
Bone 10 (3.0)
Liver  6 (1.8)
Othersa  37 (11.2)
aOthers: kidney, breast, parotid gland, cerebrospinal f luid, 
brain, ovary, testis, skin, nasal cavity, lacrimal duct, conjunc-
tiva, eye lid, trachea, glottis, thyroid gland, and thyroid carti-
lage.
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have a lower OS rate. In addition, poor performance 
status (ECOG > 1), B symptoms, elevated serum LDH 
level, HBsAg (+), hepatitis C virus (HCV) Ab (+), Ep-
stein-Barr virus (EBV) (+), extranodal site number > 
1, T-cell subtype, high-intermediate/high risk IPI, 
advanced stage (Ann Arbor stage III/IV), and no CR af-
ter first-line treatment were found to be significantly 
poor prognostic factors by univariate analysis (Table 
6). Among these factors, age ≥ 62 years, T-cell subtype, 
and no CR after first-line treatment were verified to be 
significantly poor prognostic factors by multivariate 
analysis (Table 7).
DISCUSSION
Pathological distributions and baseline characteristics 
of WR-NHL patients in Korea were analyzed. Similar 
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Figure 1. Overall survival of Waldeyer’s ring non-Hodgkin lymphoma according to stage (A) and International Prognostic 
Index (B).
A B
Table 4. Extranodal site of involvement according to involvement of Waldeyer’s ring 
Extranodal site Bone marrow
Gastrointestinal 
tract
Bone
Lung/pleura/
pericardium
Liver Othersa
Base of tongue 1 0 0 1 0 1
Tonsil 17 18 6 6 2 17
Oral cavity 0 0 0 0 0 0
Salivary gland 2 1 0 1 1 6
Oropharynx 1 2 1 0 2 3
Hypopharynx 0 0 0 0 0 0
Nasopharynx 1 0 0 1 0 3
Location of WR not specified 8 3 3 7 1 7
Total 30 24 10 16 6 37
WR, Waldeyer’s ring.
aOthers: kidney, breast, parotid gland, cerebrospinal fluid, brain, ovary, testis, skin, nasal cavity, lacrimal duct, conjunctiva, eye 
lid, trachea, glottis, thyroid gland, and thyroid cartilage.
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to previous studies, the most frequent pathological 
subtype was DLBCL [9,13,14]. While in general the DL-
BCL subtype involves the bone marrow in 10% to 15% 
of cases, the DLBCL subtype involving the bone mar-
row comprises only 3.3% of WR-NHL cases; further-
more, relatively few of these cases have any extranodal 
involvement [5,7,9].
NK/T-cell lymphoma and peripheral T-cell lympho-
ma occurred more frequently in this study than has 
been reported from Western nations. Our data showed 
a low incidence of follicular lymphoma (1.2%); howev-
er, it is the second most common lymphoma subtype 
of WR-NHL in Western populations [15]. Our results 
were similar to those reported in Japanese and Chi-
nese studies [7,15-17]. The distribution of histological 
subtypes depends on regional and racial differences; 
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Figure 2. Progression-free survival (A), disease-free survival (B), and overall survival (C) of Waldeyer’s ring non-Hodgkin 
lymphoma with localized disease according to treatment. CTx, chemotherapy; RTx, radiotherapy; OP, surgical resection +/- 
chemotherapy or radiotherapy.
A B C
Table 5. Treatment according to Waldeyer’s ring non-Hodgkin lymphoma subtype 
Lymphoma subtype No. (%) CTx RTx CTx + RTx SR
Supportive 
care
Diffuse large B-cell lymphoma 241 (73.4) 170 6 50 13 2
Mantle cell lymphoma  9 (2.7) 9 0 0 0 0
Follicular lymphoma   4 (1.2) 2 0 2 0 0
Small lymphocytic lymphoma    3 (0.9) 1 2 0 0 0
Burkitt lymphoma  5 (1.5) 5 0 0 0 0
Extranodal marginal zone lymphoma of MALT  11 (3.4) 1 7 0 1 2
T-cell-rich B-cell lymphoma   3 (0.9) 3 0 0 0 0
Lymphoblastic lymphoma   2 (0.6) 2 0 0 0 0
Nodal marginal zone lymphoma   6 (1.8) 2 1 0 2 1
Peripheral T-cell lymphoma 14 (4.3) 11 0 3 0 0
Nasal NK/T-cell lymphoma 14 (4.3) 7 0 6 1 0
Angioimmunoblastic T-cell lymphoma  9 (2.7) 9 0 0 0 0
Anaplastic large T-cell lymphoma   3 (0.9) 3 0 0 0 0
Other T-cell lymphomas   4 (1.2) 2 0 2 0 0
Total 328 227 16 63 17 5
CTx, chemotherapy; RTx, radiotherapy; SR, surgical resection; MALT, mucosa-associated lymphoid tissue.
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therefore, this distribution might be related to suscep-
tibility of the host to the EBV and human T-cell leuke-
mia virus [13,18-20]. We also performed serum immu-
nological studies of EBV infection in some patients (n 
= 79). Of 17 patients positive for EBV antibodies, five 
had T-cell lineage WR-NHL. EBV infection did not af-
fect the survival outcomes; however, further evaluation 
to confirm the relationship between EBV infection 
and T-cell lineage WR-NHL may be helpful to deter-
mine the etiology of WR-NHL.
DLBCL has a heterogeneous nature, and it varies in 
its response to treatment as well as in its prognosis 
[15,21-23]. While it was reported that the germinal cen-
ter B-cell-like (GCB) type has a better response to 
treatment, DLBCL with BCL2 rearrangement showed 
a poor response to treatment [24-27]. In this study, tis-
Table 6. Univariate analysis of prognostic factors for patients with Waldeyer’s ring non-Hodgkin lymphoma
Parameter
3-Year PFS 3-Year DFS 3-Year OS
 % p value % p value  % p value
Age ≥ 62 yr 72.3 vs. 85.9 0.030  70.1 vs. 88.6 0.004  61.0 vs. 83.4 < 0.001
ECOG > 1 36.6 vs. 82.6 0.015   57.1 vs. 82.6 0.327   30.1 vs. 76.2 < 0.001
B symptom (+) 79.1 vs. 80.7 0.907  75.5 vs. 82.5 0.285  60.9 vs. 76.4 0.019
Elevated serum LDH 66.1 vs. 83.1 < 0.001 62.9 vs. 84.1 0.022   61.7 vs. 76.9 0.002
HBsAg (+) 78.5 vs. 83.3 0.323  83.1 vs. 84.4 0.660 68.8 vs. 75.5 0.013
HCV Ab (+) 37.5 vs. 85.1 0.015      0 vs. 83.4 0.502       0 vs. 71.2 < 0.001
EBV (+) 75.3 vs. 87.0 0.030 80.8 vs. 84.2 0.430   55.1 vs. 74.3 0.005
Extranodal site > 1 79.0 vs. 80.7 0.563 76.7 vs. 82.3 0.345   55.7 vs. 76.7 0.011
T-cell subtype 57.0 vs. 84.3 < 0.001 76.0 vs. 82.3 0.159   50.7 vs. 78.0 < 0.001
High-intermediate or high IPI 67.0 vs. 84.0 0.017 64.9 vs. 86.1 0.005   51.9 vs. 80.6 < 0.001
Advanced stage 72.8 vs. 84.2 0.043 73.8 vs. 85.8 0.069  60.6 vs. 80.8 0.001
No CR 48.1 vs. 90.3 < 0.001 34.9 vs. 87.1 < 0.001   57.2 vs. 82.9 < 0.001
PFS, progression-free survival; DFS, disease-free survival; OS, overall survival; ECOG, Eastern Cooperative Oncology Group; 
LDH, lactate dehydrogenase; HCV, hepatitis C virus; EBV, Epstein-Barr virus; IPI, International Prognostic Index; CR, 
complete remission.
Table 7. Multivariate analysis of prognostic factors for overall survival in patients with Waldeyer’s ring non-Hodgkin lymphoma
Parameter HR (95% CI) p value 
Age ≥ 62 yr 2.645 (1.427–4.904) 0.001
ECOG > 1 0.903 (0.306–2.856) 0.906
B symptom (+)  0.983 (0.464–2.086) 0.800
Elevated serum LDH level 1.017 (0.788–1.312) 0.644
HBsAg (+)  1.089 (0.409–2.901) 0.294
Anti-HCV Ab (+)  6.380 (0.777–52.415) 0.081
EBV (+) 2.592 (0.897–7.483) 0.078
Extranodal site > 1 1.214 (0.517–2.847) 0.711
T-cell subtype 2.944 (1.410–6.147) < 0.001
High-intermediate or high IPI  1.140 (0.770–1.688) 0.466
Advanced stage 1.333 (0.563–3.154) 0.637
No CR 1.536 (1.270–1.856) < 0.001
HR, hazard ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; HCV, 
hepatitis C virus; EBV, Epstein-Barr virus; IPI, International Prognostic Index; CR, complete remission.
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sues from the WR of 56 patients were subjected to im-
munohistochemical evaluation of markers such as 
CD10, BCL6 and MUM1. These patients were divided 
into GCB and non-GCB groups according to the Han’s 
criteria [27], and the differences in survival between 
the two groups were determined. There was no statis-
tically signif icant difference between the groups, 
which could be due to evaluation of an insufficient 
number of patients to conf irm the immunohisto-
chemical staining results. 
In the current study, among those with localized 
disease, the surgical resection group showed improved 
survival compared with the chemotherapy or chemo-
therapy plus radiotherapy group. Almost all patients 
in the surgical resection group had the DLBCL sub-
type and underwent tonsillectomy for confirmation of 
the pathological diagnosis. Therefore, it is possible 
that the surgical resection group had better survival, 
because tonsillar involvement itself may be a favorable 
prognostic factor compared with involvement of other 
sites. Mohammadianpanah et al. [28] reported that 
tonsillar lymphoma tended to be localized and to have 
a good outcome. They showed that combined chemo-
therapy and radiation therapy was highly effective and 
probably curative for the majority of patients with 
stage I, nonbulky disease [28]. Our data also showed 
relatively good outcomes in the chemotherapy and the 
chemotherapy plus radiotherapy group. However, all 
patients in the surgical resection group survived, and 
all but one received chemotherapy or chemoradiother-
apy after surgery. Although a small number of patients 
were analyzed in our study, it is speculated that in pa-
tients with localized DLBCL, surgical resection fol-
lowed by chemotherapy or chemoradiotherapy might 
be a better treatment than other modalities. 
Prognostic factors related to survival were subjected 
to univariate and multivariate analyses. The T-cell lin-
eage of WR-NHL was a significant poor prognostic 
factor. These findings could be related to the greater 
extranodal involvement, especially in the bone mar-
row and liver, at the time of diagnosis in these pa-
tients, compared with those with the B-cell subtype. 
Involvement of remote lymph nodes or extranodal in-
volvement was found in the majority of T-cell lineage 
NHL cases. Conversely, most B-cell lineage NHL cases 
presented with spreading to adjacent lymph nodes 
[9,17]. The IPI and Ann Arbor stage are commonly 
used to assess prognosis in WR-NHL. Age ≥ 62 years, 
elevated LDH levels, and advanced stages were signifi-
cant poor prognostic factors for survival [5,14,17]. Fail-
ure to achieve CR after first-line treatment was also a 
signif icant poor prognostic factor according to the 
multivariate analysis.
In conclusion, DLBCL was found to be more fre-
quent in Korea than reported in WR-NHL studies 
from other nations. And T-cell lineage NHL was found 
to occur more frequently than follicular lymphoma. 
T-cell lineage NHL, age ≥ 62 years, and failure to 
achieve CR after first-line treatment were all signifi-
cant poor prognostic factors for overall survival ac-
cording to the multivariate analysis.
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